Hai T T, Nelson D, Pereira D, Srnak A
Blood Substitutes Program, Baxter Healthcare Corporation, Round Lake, IL 60073.
Artif Cells Blood Substit Immobil Biotechnol. 1994;22(3):923-31. doi: 10.3109/10731199409117931.
By employing proprietary polymerization agents possessing specific binding groups and by completing diaspirin crosslinked hemoglobin (DCLHb) polymerization under specific conditions, we have selectively achieved the following objectives: (1) the P50 was adjusted to the physiologic range or left- or right-shifted; (2) the surface of DCLHb was modified ("decorated"); (3) DCLHb was polymerized but not decorated; (4) DCLHb was polymerized and decorated; or (5) DCLHb was site-specifically modified and polymerized.
通过使用具有特定结合基团的专有聚合剂,并在特定条件下完成双阿司匹林交联血红蛋白(DCLHb)的聚合,我们有选择地实现了以下目标:(1)将P50调整到生理范围或向左或向右移动;(2)修饰(“装饰”)DCLHb的表面;(3)使DCLHb聚合但不进行修饰;(4)使DCLHb聚合并进行修饰;或(5)对DCLHb进行位点特异性修饰并聚合。